To examine the antiobesity effect of epigallocatechin gallate (EGCG), a green tea bioactive polyphenol in a mouse model of diet-induced obesity. METHODS: Obesity was induced in male New Zealand black mice by feeding of a high-fat diet. EGCG purified from green tea (TEAVIGOt) was supplemented in the diet (0.5 and 1%). Body composition (quantitative magnetic resonance), food intake, and food digestibility were recorded over a 4-week period. Animals were killed and mRNA levels of uncoupling proteins (UCP1-3), leptin, malic enzyme (ME), stearoyl-CoA desaturase-1 (SCD1), glucokinase (GK), and pyruvate kinase (PK) were analysed in different tissues. Also investigated were acute effects of orally administered EGCG (500 mg/kg) on body temperature, activity (transponders), and energy expenditure (indirect calorimetry). RESULTS: Dietary supplementation of EGCG resulted in a dose-dependent attenuation of body fat accumulation. Food intake was not affected but faeces energy content was slightly increased by EGCG, indicating a reduced food digestibility and thus reduced long-term energy absorption. Leptin and SCD1 gene expression in white fat was reduced but SCD1 and UCP1 expression in brown fat was not changed. In liver, gene expression of SCD1, ME, and GK was reduced and that of UCP2 increased. Acute oral administration of EGCG over 3 days had no effect on body temperature, activity, and energy expenditure, whereas respiratory quotient during night (activity phase) was decreased, supportive of a decreased lipogenesis and increased fat oxidation. CONCLUSIONS: Dietary EGCG attenuated diet-induced body fat accretion in mice. EGCG apparently promoted fat oxidation, but its fat-reducing effect could be entirely explained by its effect in reducing diet digestibility.
Introduction
Green tea contains high levels of polyphenols, which are supposed to have a number of positive health effects in the prevention of lifestyle-related diseases including cardiovascular disease and carcinogenesis. The main tea polyphenols are catechins whose reported physiological effects include antioxidant, antihypertensive, anticarcinogenic, and hypocholesterolemic action. [1] [2] [3] Tea catechins are also thought to be useful as antiobesity compounds since they reduced dietinduced obesity in mice, rats, and humans. [4] [5] [6] [7] [8] It has been shown in vitro that catechin enriched green tea extracts could increase sympathetic mediated thermogenesis in brown adipose tissue (BAT). 9 Also, green tea extracts were found to increase energy expenditure in mice supposedly by activating brown fat thermogenesis. 10 In mice fed a high-fat diet tea catechins exerted an antiobesity effect and stimulated lipid catabolism in liver. 4, 6 Furthermore, in human studies, it was shown that acute intake of a tea catechin extract increased 24-h energy expenditure 11 and decreased body fat content after 12 weeks of intervention. 8 However,
beside catechins, there are also significant amounts of caffeine in green tea extracts, which could also at least in part contribute to the thermogenic effect of green tea extracts. The most abundant catechin from green tea is (À)-epigallocatechin gallate (EGCG), which has been shown to have a number of different cellular and molecular effects related to the health-promoting action of tea catechins. The effect of EGCG on obesity development and energy metabolism in vivo has not been studied in detail. Objective of this study was therefore to investigate the effect of EGCG on obesity and energy metabolism in NZB mice, an inbred mouse strain highly susceptible to development of dietinduced obesity. TEAVIGOt is an extract of green tea (Camellia sinensis), which contains over 94% of EGCG and less than 0.1% caffeine. We evaluated the acute effects of orally administered TEAVIGOt on body temperature, energy expenditure, and substrate oxidation, and also the long-term effects of dietary supplementation on development of dietinduced obesity in mice. Since uncoupling proteins (UCPs) are considered to be implicated in thermogenesis and energy metabolism, [12] [13] [14] [15] we investigated the effect of dietary EGCG supplementation on UCP1-3 gene expression in various organs. Furthermore, we analysed expression of key genes in lipid and glucose metabolism in liver and adipose tissue.
Methods

Animals and diets
Male New Zealand black (NZB) mice were purchased (HarlanWinkelmann, Paderborn, Germany) at 4 weeks of age. Mice were maintained single, under standard conditions at 221C and a 12 h:12 h dark-light cycle with food and water provided ad libitum. Animal maintenance and experiments were in accordance with the guidelines of the ethics committee of the Ministry of Agriculture and Environment (State Brandenburg, Germany). Mice used for acute studies were fed a standard rodent chow diet containing (w/w) 19% protein, 4% fat, and 50.5% carbohydrates (Altromin 1321, Lage, Germany) provided as pellets. In the chronic feeding, experiment mice were fed a commercial high-fat diet (HFD) containing (w/w) 17% protein, 15% fat, and 42% carbohydrates (Altromin C1057, Lage, Germany) provided in powdered form. Energy content of standard chow and HFD as determined by bomb calorimetry was 17.1 and 19.7 kJ/g, respectively.
Experimental setup
In the first experiment we investigated the chronic effect of dietary supplied TEAVIGOt on development of dietary induced obesity in NZB mice. TEAVIGOt is a highly purified extract from the leaves of green tea (C. sinensis) containing min 94% EGCG, max 5% other catechins (max 3% epicatechin gallate), max 0.1% gallic acid, and max 0.1% caffeine. TEAVIGOt was supplied by DSM Nutritional Products, Basel, Switzerland. In total, 33 male NZB mice aged 4-5 weeks were put on a HFD for 4 weeks in order to induce obesity. Animals were housed single, food and water were provided ad libitum. In the fourth week, energy digestion was determined in all animals. After 4 weeks of high-fat feeding, mice were randomly allocated to three groups of 11 animals each and baseline measurement of body composition was performed (day 0). For the next 4 weeks animals received high-fat chow as before, supplemented with 0% (control), 0.5%, and 1% (w/w) TEAVIGOt. TEAVIGOt was mixed into the chow supplied in powder form. Aliquots of chow were vacuum sealed and stored at 51C until used. Food and water were always supplied ad libitum. Body weight and food intake were determined 2-3 times per week. Body composition and blood glucose were measured after 11 and 28 days. Since animals were obviously stressed in the metabolic cages and lost some weight, measurement of energy digestion was repeated in four animals only during the 4th week. The remaining seven animals per group were killed on day 29, organ weight was recorded (liver, stomach, kidney, epididymal white adipose tissue (WAT)) and tissue samples were frozen in liquid nitrogen for subsequent RNA extraction (epididymal WAT, brown adipose tissue (BAT), liver, hindlimb skeletal muscle). Blood was collected, plasma prepared and stored for subsequent analysis.
In the second experiment, the acute effect of orally administered TEAVIGOt was investigated in 8-9-week-old male NZB mice fed a standard diet. Mice had implanted transponders for measurement of body temperature and activity. In total, 12 mice were randomly divided into two groups. They were orally dosed with 0.2 ml water on day 1, followed by 3 days of daily application of water (control, n ¼ 6) or EGCG at 500 mg/kg dissolved in water (EGCG group, n ¼ 6). All applications were performed between 1600 and 1700, that is, 1-2 h before onset of dark period. During the 4 days energy expenditure, body temperature and locomotor activity were measured continuously from 1100 to 1000 the next morning. The first day was considered adaptation period and not included in analysis.
Energy digestion
Energy digestion in the chronic experiment was determined by subtraction of energy content in faeces from energy content of food consumed. For this mice were placed individually in metabolic cages for 4 days. These cages allowed determination of food intake and quantitative collection of faeces. Faeces were dried, and energy content determined by means of an adiabatic bomb calorimeter (IKACalorimeter C 5000, IKA-Werke GmbH & Co. KG, Staufen, Germany). Total energy content in food was measured likewise in duplicate samples of the three different diets. Addition of EGCG had no effect on dietary total energy content which was 19.65 kJ/g.
Body composition and blood glucose
Body fat content was measured in conscious animals between 0700 and 1000 by quantitative magnetic resonance (QMR) (Bruker's Minispec MQ10, Houston, TX, USA). This is a method developed specifically for non invasive, rapid EGCG prevents obesity S Klaus et al determination of body composition in conscious mice. 16 Lean body mass was calculated by subtracting body fat values from body weight obtained by weighing prior to NMR measurement. After QMR measurement, blood glucose was determined in blood from the tail using a common blood glucose sensor (Medisense Q.I.D., Abbott Laboratories, IL, USA). Measurements were performed at day 0, 11, and 28 of dietary intervention.
Plasma metabolites
Plasma metabolites were determined in plasma obtained from animals killed after 4 weeks of dietary intervention. Circulating free fatty acids (FFA) were determined using NEFA C kit (Wako Chemicals GmbH, Neuss, Germany). The other circulating metabolites were determined using colorimetric and enzymatic standard methods (Cobas Mira, Hoffmann La Roche AG, Grenzach-Whylen, Germany).
Body temperature and activity
Core body temperature (T b ) and activity were measured in 6-min intervals in standard cages using passive telemetry transponders (series 4000, Mini Mitter Inc., Sunriver, Oregon, USA). Transponders were implanted into the abdominal cavity under anaesthesia (ketaminhydrochlorid 80 mg/kg and xylazin (Rompun) 16 mg/kg) (Ketamin: Gräub, A Albrecht, Aulendorf, Germany; Rompun: BayerVital, Leverkusen, Germany) at least 1 week before the start of experiments to allow recovery of animals. Measurements were performed simultaneously with indirect calorimetry measurements. Data were recorded every 6 min and hourly means for every animal were calculated.
Energy expenditure
Energy expenditure was measured by indirect calorimetry in individual mice as described before [17] [18] [19] using an open respirometric system (gas analysers: Magnos 16 and Uras 14, Hartmann & Braun, Frankfurt/Main, Germany). Respiratory quotient (RQ ¼ VCO 2 /VO 2 ) and total energy expenditure (TEE in kJ/day) were calculated according to Weir. 20 Measurements were performed in 6-min intervals over a period of 23 h (1200 to 1100 the next day). Hourly means were calculated for every animal.
Gene expression
Total RNA from individual tissues (epididymal WAT, interscapular BAT, liver, and hind limb skeletal muscle) was extracted using a single-step acid phenol-guanidine method, and gene expression was analysed by Northern blot as described before. 21 In brief, 10 mg of total RNA was separated by electrophoresis in a 1% agarose gel containing formaldehyde and blotted by capillary transfer to a nylon membrane (Hybond N, Amersham Biosciences, Freiburg, Germany). The blots were probed with 32 P-labelled probes in a hybridization solution containing sodium phosphate (0.5 M), EDTA (1 mM), sodium dodecyl sulphate (SDS) (7%), and bovine serum albumin (1%) at 631C over night, and washed twice with saline sodium citrate (SSC) 2 Â SSC-0.1% SDS for 20 min at room temperature, twice with 0.1 Â SSC-0.1% SDS for 20 min at 421C and twice with 0.1 Â SSC-0.1% SDS for 20 min at 631C. An Instant Imager (A202401, Canberra Packard GmbH, Dreieich, Germany) was used for analysis and quantification of radio-labelled signals. For hybridization complete cDNA probes for rat UCP1 and UCP2 were kindly provided by Prof. Daniel Ricquier (CNRS, Paris, France) as reported before. 22 For UCP3, a 305 bp cDNA fragment was obtained by reverse transcription and PCR amplification of mRNA isolated from rat tissues using following UCP3 specific primers: GTCCGATTTCAAGCCAT GAT (forward) and CGGGTCTTTACCACATCCC (reverse).
For leptin a 244-bp cDNA fragment was obtained by reverse transcription and PCR amplification of rat mRNA isolated from white fat using following leptin specific primers: CCTGTGGCTTTGGTCCTATCTG (forward) and AGGCAA GCTGGTGAGGATCTG (reverse). Mouse specific cDNA probes for malic enzyme (ME), glucokinase (GK), pyruvate kinase (PK) and stearoyl-CoA desaturase-1 (SCD1) were those used by Becker et al, 23 kindly provided by Professor H-G Joost (DIfE, Germany). 
Statistical analysis
Results
Effects of chronic EGCG supplementation
Dietary supplementation with EGCG significantly affected body weight development as shown in Figure 1a . EGCG dose dependently reduced the body weight increase observed after feeding of a HFD. Control animals gained twice as much body weight during the 4-week treatment as animals supplemented with 1% EGCG in the diet (Table 1) . This was not due to a decreased food intake since neither daily food intake ( Figure 1b ) nor total food intake during the treatment period (Table 1) was changed. The reduced body weight gain induced by EGCG was exclusively due to a reduction in body fat (Figure 2a ). Lean body mass development was not affected by EGCG, the increase in lean body mass was similar in all groups (Figure 2b ). Body fat gain of mice supplied with 1% EGCG in the diet was more than three times lower (2.5 g) than that of control mice (7.9 g, Table 1 ). EGCG induced reduction in overall body fat was also EGCG prevents obesity S Klaus et al reflected by a reduction in epididymal fat pads. Liver absolute and relative weights on the other hand were not affected by EGCG (Table 2) . Prior to the 4 weeks intervention period, all animals were housed in metabolic cages over a 4-day period for collection of faeces. Mean energy content of faeces was 14.4570.03 kJ/g dry weight. Since all animals had lost some weight during this period and because the variation in faeces energy content was very low (1.3%), only a subgroup of four animals was used for determination of faeces energy content during the last week of dietary supplementation with EGCG.
Faeces energy content was found to be slightly, but significantly and dose dependently increased by EGCG supplementation (Table 1) , suggesting a lower intestinal energy extraction.
Plasma metabolites (in the fed state) were only marginally affected by EGCG supplementation. There was no effect on blood glucose and plasma NEFA concentrations, whereas triglyceride levels were found to be reduced in the 0.5% EGCG group only. EGCG prevents obesity S Klaus et al Table 3 shows the effect of EGCG supplementation on expression of selected genes in different organs. No changes in gene expression were observed in BAT. In epididymal WAT, there was a significant, dose-dependent reduction in leptin gene expression induced by EGCG. SCD1 expression in WAT was also downregulated in the EGCG supplemented groups. Pronounced changes in gene expression were also found in liver: UCP2 expression was increased whereas expression of GK, SCD1 and ME were reduced by EGCG. Interestingly, UCP2 expression was increased in liver but decreased (although not significantly) in skeletal muscle (Table 3) .
Acute effects of oral EGCG application
Since dietary EGCG supplementation was found to have significant long-term effects on body composition, we conducted a second experiment in order to evaluate acute effects of EGCG on energy homeostasis and substrate oxidation. Table 4 shows parameters of energy metabolism in mice receiving an oral administration of EGCG (500 mg/ kg body weight) once a day for 3 consecutive days. Body weight development during this time and also overall food intake was not affected by EGCG. Also, mean daily values for body temperature, activity and energy expenditure were unaffected by the treatment. Figure 3 shows the daily patterns of body temperature (a), locomotor activity (b), energy expenditure (c) and respiratory quotient (RQ) (d) during the 3 days of oral application. There was no effect of EGCG on the pattern of body temperature, locomotor activity, and energy expenditure. But interestingly, RQ during the night phase tended to be decreased by repeated treatment with EGCG (Figure 3d ), this being most obvious on the third day. Mean RQ was reduced by 500 mg/kg EGCG at third day of treatment, the data reaching borderline significance (Table 4 , P ¼ 0.053).
Discussion
Our results indicate that the tea catechin EGCG is able to prevent the development of diet-induced obesity in a mouse model of high obesity susceptibility. This is in agreement with and an extension of previous studies in mice and rats showing reduced adiposity after dietary supplementation with green tea extracts. [4] [5] [6] [7] Our data also show that among the tea catechins EGCG is highly effective and sufficient in reduction of diet-induced obesity in mice. NZB mice are closely related to NZO (New Zealand obese mice), which represent a polygenic model of obesity and insulin resistance. 24, 25 Previous studies in our group showed that NZB mice are highly susceptible to the development of EGCG prevents obesity S Klaus et al diet-induced obesity (Ortmann S, Klaus S, unpublished data). Accordingly, feeding of an HFD increased body fat content by about 200% within 4 weeks. This was markedly attenuated by EGCG treatment. The body weight gain of about 6 g observed in the 1% EGCG group was very similar to the body weight gain of NZB mice of same age fed a standard low fat chow diet (data not shown). More importantly, EGCG treatment affected body fat only and did not change lean body mass. Total body fat gain was over three times higher in control mice than in mice receiving 1% of EGCG. Interestingly, 0.5% EGCG reduced body fat gain by 3.7 g and the additional reduction by 1% EGCG was only 1.7 g. This indicates that 0.5% supplementation is already close to the maximum obtainable effect. 
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Overall food intake was not affected by EGCG supplementation, which is in accordance with data from Murase et al, 6 who fed mice with an HFD supplemented with 0.1-0.5% tea catechins. On the other hand, intraperitoneal injection of EGCG into rats was found to decrease food intake significantly, 26 suggesting that the mode of application is an important factor. This is probably related to the bioavailability of catechins, which is rather low in general. 27, 28 Although the reduction in body fat by EGCG was not due to a decreased food intake, energy content of faeces was slightly, but significantly increased with increasing doses of EGCG, suggesting a lower intestinal energy extraction. As we did not analyse faeces composition, it is not clear if this is related to a decreased intestinal fat or carbohydrate extraction, but previous studies indicate that EGCG decreases fat absorption. 29 On the other hand, it has also been reported that tea catechins including EGCG could inhibit the sodiumdependent glucose transporter. 30 If the reduced energy absorption is taken into account, EGCG resulted in a slightly (but not significantly) reduced total energy digestion of about 200 kJ throughout the 4-week treatment period (control: 2790 kJ, EGCG 0.5%: 2565 kJ, EGCG 1%: 2587 kJ). In total, 200 kJ correspond to the energy content of approximately 5 g lipids, which is very close to the difference in body fat gain between the control group and the 1% EGCG group. Therefore, the rather small reduction in energy absorption could explain most of the reduced body fat accumulation over the experimental period of 4 weeks. However, the distinct effects of EGCG on gene expression as well as its short-term effect on substrate oxidation also point to an additional distinct metabolic effect of EGCG. Significant differential effects of EGCG supplementation could be seen on gene expression of different UCPs. These are mitochondrial proteins considered to be involved in energy metabolism.
31 UCP1 is present in BAT only and responsible for BAT thermogenesis. This as well as UCP1 gene expression is stimulated by sympathetic activation. 32 EGCG had no effect on UCP1 gene expression in brown fat suggesting that EGCG does not act via an increase of brown fat thermogenesis. The exact biological roles of UCP2 and UCP3
are not yet clear, their proposed functions include control of reactive oxygen species, regulation of ATPsynthesis, and regulation of fatty acid oxidation in addition to a possible thermogenic function. Overall, gene expression of UCP2 and 3 is affected by situations characterized by changes in energy expenditure and substrate oxidation. [12] [13] [14] [15] UCP2 expression in liver was doses dependently increased by EGCG and doubled in the 1% group. In skeletal muscle, however, UCP2 expression was not increased, on the contrary, it was rather decreased, although not reaching statistical significance due to high interindividual variability. The increase of UCP2 expression in liver is compatible with an increased energy metabolism in liver induced by EGCG and could possibly be the consequence of an increased fatty acid oxidation. We have observed previously that UCP2 expression in liver and muscle is regulated differently (Petzke KJ, Klaus S, unpublished data), which was again supported by this study. Furthermore, the increase in UCP2 expression in liver could also be a means of limiting ROS production, since EGCG was reported to act as a pro-oxidant in hepatoma cells in vitro.
33
SCD is the rate-limiting enzyme in the synthesis of monounsaturated fatty acids and SCD1 is strongly expressed in liver and adipose tissue.
34 SCD1 knockout mice show reduced adiposity, decreased lipid synthesis and increased liver fatty acid oxidation, and SCD1 is therefore considered as an important metabolic control point. 34, 35 EGCG treatment downregulated SCD1 gene expression in liver and even more pronounced in WAT, which could be one reason for the reduced fat accumulation. This is in line with the reduced expression of ME, an enzyme involved in lipid synthesis, which was found to be upregulated in obese NZO mice, 23 a mouse strain closely related to NZB mice. It is interesting to note that in contrast to WAT, SCD1 expression in BAT was not affected by EGCG, suggesting a specific effect of EGCG on lipid storing white adipose but no action on thermogenic brown fat. GK is a key enzyme of liver glycolysis 36 and its downregulation by EGCG supplementation is in line with the reduced RQ, which is indicative of reduced glucose oxidation. Leptin expression in WAT was dose-dependently decreased by EGCG. Since leptin expression in white fat is highly correlated with fat mass, 37 this decrease could be a simple consequence of the reduced mass of epididymal WAT depots. However, it should be noted that the reduction in leptin gene expression induced by EGCG is over proportional compared to the reduction in fat mass. It can thus not be excluded that there might also be a specific EGCG effect on WAT, which might be supported by the pronounced effect on SCD1 gene expression in WAT. One limitation of the gene expression data is the fact that they represent the end point of the study only. At this time, body fat was significantly decreased in the EGCG supplemented groups. It can thus not be excluded that the observed changes in gene expression are mainly a consequence of the altered energy homeostasis. Further studies of gene expression should thus be performed at an earlier time point, when changes in body composition are not yet manifest.
Previous studies have shown stimulatory effects of green tea extracts on BAT thermogenesis and energy expenditure both in mice and in humans. 11, 10 It has been proposed that green tea extracts increase energy expenditure and fat oxidation by increasing and/or prolonging noradrenaline action. 38 This is thought to result from a synergism between the actions of caffeine and catechins. 11 Caffeine inhibits posphodiesterase, an enzyme that degrades intracellular cyclic AMP, and antagonizes the negative effect of adenosine on noradrenaline release. 39 Catechins on the other hand inhibit catechol O-methyltransferase (COMT), the enzyme that degrades noradrenaline. 40 To our knowledge, the effect of EGCG alone on energy and substrate metabolism in vivo EGCG prevents obesity S Klaus et al
has not yet been investigated. Our data do not support a principal action of EGCG on activation of sympathetic nervous system. Energy expenditure and body temperature were not increased by acute application of EGCG and also BAT thermogenesis did not seem to be enhanced since UCP1 expression in BAT was not affected. On the other hand, RQ during night was reduced by EGCG application indicating changes in substrate utilization. The increase in RQ to values over 1.0 during the night (ie active and feeding phase) observed in control animals most probably reflects an increased carbohydrate fuelled lipogenesis in NZB mice. (In this experiment mice were fed a high-carbohydrate/low-fat diet). The fact that EGCG lowers RQ mainly during the night, that is, feeding phase could thus indicate an inhibitory effect on lipogenesis. However, a stimulatory effect on fatty acid oxidation cannot be excluded perhaps through sympathetic control of fat oxidation by the known inhibitory effect of EGCG on COMT, an enzyme that degrades noradrenaline. This is indeed supported by previous studies, which have demonstrated a stimulation of lipid catabolism in liver by green tea catechins enriched in EGCG. 6 Taken together, the data on RQ and gene expression suggest a reduction of glucose catabolism and lipogenesis by EGCG, which in turn favours lipid catabolism.
Conclusions
EGCG prevented the development of diet-induced obesity in obesity prone mice. There is no evidence that this is caused by an increased brown fat thermogenesis since neither energy expenditure nor UCP1 expression in BAT were increased. This does not support an activation of the sympathetic nervous system as the primary mechanism of EGCG action. It seems that EGCG has two distinct effects regarding energy balance and substrate oxidation. On the one hand, there are possibly direct metabolic effects of EGCG on liver and white fat metabolism as supported by the reduction in RQ and the observed changes in gene expression. On the other hand, its long-term fat-reducing properties could be entirely due to the EGCG effect in reducing diet digestibility. Further experiments should be performed to elucidate the mechanisms by which EGCG affects diet digestibility, and to evaluate the direct effect of EGCG on hepatocytes and adipocytes in vitro. Additionally, experiments using tracer techniques should be employed to evaluate the effect of EGCG on lipogenesis, carbohydrate, and fat oxidation in vivo.
